Sahar Fattani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sahar Fattani has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Adina Qu
Department of Biomedical Science, Discipline of Pharmacology, Edward Via College of Osteopathic Medicine (VCOM), 4408 Bon Aire Drive, Monroe, LA 71203, USA
1 shared publication Arthur Wu
Cedars‐Sinai Medical Center Division of Otolaryngology California Los Angeles USA
1 shared publication- Debasis Mondal
DeBusk College of Osteopathic Medicine, Lincoln Memorial University, Knoxville, TN 37932, USA
1 shared publication Gene Liu
Cedars‐Sinai Medical Center Division of Otolaryngology California Los Angeles USA
1 shared publication- Haneen Hamed
Department of Biomedical Science, Discipline of Pharmacology, Edward Via College of Osteopathic Medicine (VCOM), 4408 Bon Aire Drive, Monroe, LA 71203, USA
1 shared publication - Kayla Gray
Department of Biomedical Science, Discipline of Pharmacology, Edward Via College of Osteopathic Medicine (VCOM), 4408 Bon Aire Drive, Monroe, LA 71203, USA
1 shared publication
Latest Publications
- Open Access
Repurposing Antipsychotic Agents in Oncology: Mechanistic Rationale, Emerging Evidence, and Therapeutic Potential
Antipsychotic agents—spanning first-, second-, and third-generation drug classes—are emerging as mechanistically diverse candidates for repurposing in oncology. Although developed to modulate dopaminergic and serotonergic neurotransmission, some of these compounds exert pleiotropic effects on cancer cell survival, metabolism, and stemness. Across multiple malignancies, antipsychotics disrupt oncogenic signaling networks including PI3K/Akt/mTOR, STAT3/5, MAPK/ERK, and Wnt/β-Catenin, impair lysosomal and autophagic flux, and induce mitochondrial and calcium-dependent metabolic stress. Notably, several phenothiazines and dopamine-modulating agents selectively reduce cancer stem cell populations, suggesting potential utility in limiting recurrence and mitigating therapeutic resistance. These effects appear to involve disruption of CSC signaling pathways and interference with dopamine-dependent mechanisms that support stemness and survival. Preclinical studies consistently demonstrate antiproliferative, proapoptotic, antimetastatic, and chemosensitizing effects, whereas early clinical investigations demonstrate target engagement and feasibility but do not establish anticancer efficacy. Clinical trials of thioridazine in acute myeloid leukemia and chlorpromazine in glioblastoma show evidence of pharmacodynamic activity in patients, though these findings remain preliminary and non-efficacy-based. However, translation remains constrained by dose-limiting toxicities, pharmacokinetic barriers, and conflicting epidemiologic signals regarding long-term carcinogenic risk. Here, we synthesize mechanistic, translational, and emerging clinical findings relevant to antipsychotic repurposing in oncology, highlight tumor contexts in which these agents may hold potential, and outline future directions including biomarker-guided patient selection, rational combination strategies, and artificial intelligence (AI)-enabled drug-repurposing pipelines. Collectively, antipsychotics represent a promising yet underexplored class of multi-targeted agents; to define their full therapeutic potential will require rigorous mechanistic validation and carefully designed clinical trials.
Open AccessRepurposing Antipsychotic Agents in Oncology: Mechanistic Rationale, Emerging Evidence, and Therapeutic Potential
Antipsychotic agents—spanning first-, second-, and third-generation drug classes—are emerging as mechanistically diverse candidates for repurposing in oncology. Although developed to modulate dopaminergic and serotonergic neurotransmission, some of these compounds exert pleiotropic effects on cancer cell survival, metabolism, and stemness. Across multiple malignancies, antipsychotics disrupt oncogenic signaling networks including PI3K/Akt/mTOR, STAT3/5, MAPK/ERK, and Wnt/β-Catenin, impair lysosomal and autophagic flux, and induce mitochondrial and calcium-dependent metabolic stress. Notably, several phenothiazines and dopamine-modulating agents selectively reduce cancer stem cell populations, suggesting potential utility in limiting recurrence and mitigating therapeutic resistance. These effects appear to involve disruption of CSC signaling pathways and interference with dopamine-dependent mechanisms that support stemness and survival. Preclinical studies consistently demonstrate antiproliferative, proapoptotic, antimetastatic, and chemosensitizing effects, whereas early clinical investigations demonstrate target engagement and feasibility but do not establish anticancer efficacy. Clinical trials of thioridazine in acute myeloid leukemia and chlorpromazine in glioblastoma show evidence of pharmacodynamic activity in patients, though these findings remain preliminary and non-efficacy-based. However, translation remains constrained by dose-limiting toxicities, pharmacokinetic barriers, and conflicting epidemiologic signals regarding long-term carcinogenic risk. Here, we synthesize mechanistic, translational, and emerging clinical findings relevant to antipsychotic repurposing in oncology, highlight tumor contexts in which these agents may hold potential, and outline future directions including biomarker-guided patient selection, rational combination strategies, and artificial intelligence (AI)-enabled drug-repurposing pipelines. Collectively, antipsychotics represent a promising yet underexplored class of multi-targeted agents; to define their full therapeutic potential will require rigorous mechanistic validation and carefully designed clinical trials.
- Open Access
- 25 December 2020
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 6 (1) , 21-24
Intra‐nasal zinc level relationship to COVID‐19 anosmia and type 1 interferon response: A proposal
Anosmia is common among COVID‐19 patients and anosmia assessment is proposed to be useful in the early diagnosis and prognosis of patients. Data on the pathogenesis of anosmia during COVID‐19 suggest potential olfactory nerve involvement. Zinc is an essential micronutrient that regulates the immune responses, and zinc deficiency is known to induce anosmia and ageusia. We previously proposed that a drop in nasal zinc level is a normal nasal immune response to acute viral infections, including SARS‐CoV‐2 infection, and play a role in the pathogenesis of anosmia. The drop in the local zinc level in response to SARS‐CoV‐2 may lead to lower type 1 interferons and shift toward Th2 immune responses; if prolonged, it may lead to increased viral replication and more severe disease. In people who are at risk for baseline systemic zinc deficiency, such as the elderly and those with chronic diseases such as, chronic lung disease, diabetes, cardiovascular disease, and cancer, SARS‐CoV‐2 infection‐induced drop in nasal zinc level may be more severe and prolonged and lead to an insufficient anti‐viral nasal immune response and control the spread of the virus systemically and to the lungs. A better understanding of the clinical implications of baseline systemic zinc deficiency on anosmia and nasal immune responses may allow the development of new treatment strategies to slow down or stop the systemic invasion of SARS‐CoV‐2.
- 25 December 2020
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 6 (1) , 21-24
Open AccessIntra‐nasal zinc level relationship to COVID‐19 anosmia and type 1 interferon response: A proposal
Anosmia is common among COVID‐19 patients and anosmia assessment is proposed to be useful in the early diagnosis and prognosis of patients. Data on the pathogenesis of anosmia during COVID‐19 suggest potential olfactory nerve involvement. Zinc is an essential micronutrient that regulates the immune responses, and zinc deficiency is known to induce anosmia and ageusia. We previously proposed that a drop in nasal zinc level is a normal nasal immune response to acute viral infections, including SARS‐CoV‐2 infection, and play a role in the pathogenesis of anosmia. The drop in the local zinc level in response to SARS‐CoV‐2 may lead to lower type 1 interferons and shift toward Th2 immune responses; if prolonged, it may lead to increased viral replication and more severe disease. In people who are at risk for baseline systemic zinc deficiency, such as the elderly and those with chronic diseases such as, chronic lung disease, diabetes, cardiovascular disease, and cancer, SARS‐CoV‐2 infection‐induced drop in nasal zinc level may be more severe and prolonged and lead to an insufficient anti‐viral nasal immune response and control the spread of the virus systemically and to the lungs. A better understanding of the clinical implications of baseline systemic zinc deficiency on anosmia and nasal immune responses may allow the development of new treatment strategies to slow down or stop the systemic invasion of SARS‐CoV‐2.